What Triveni Bio does

Triveni Bio is a clinical-stage biotechnology company developing antibody therapeutics for immunological and inflammatory (I&I) diseases, founded (corporate launch: October 2023) by Leonard Zon and Tillman Gerngross with headquarters in Watertown, Massachusetts. The company's stated approach combines three pillars: human-genetics-informed target identification, advanced antibody engineering, and novel disease biology. Its lead asset, TRIV-509, is a first-in-class, half-life-extended monoclonal antibody that dually inhibits active kallikreins 5 and 7 (KLK5/7) and is currently in a global Phase 2 proof-of-concept study in moderate-to-severe atopic dermatitis (first patient dosed September 2025). The second clinical asset, TRIV-573, is a second-generation bispecific antibody combining KLK5/7 inhibition with a validated anti-IL-13 mechanism; it entered Phase 1 in May 2026. A third program, TRIV-920, is a first-in-class antibody dually inhibiting active trypsin 1 and 2 for hereditary pancreatitis and is in preclinical development. The pipeline is positioned around an unmet need in atopic dermatitis, where roughly two-thirds of moderate-to-severe patients do not adequately respond to current Th2-focused therapies, and around a rare-disease pancreatitis indication with no approved treatments.

Triveni Bio is pre-revenue and monetises only through future pharmaceutical product sales, with planned distribution via specialty pharmacy and prescriber channels for prescription biologics in I&I. To date the company has been funded entirely by venture capital, raising approximately $272 million across a $92 million Series A (October 2023, Atlas Venture and Cormorant Asset Management co-led), a $115 million Series B (October 2024, Goldman Sachs Alternatives led) and a $65 million Series C (June 2026, Ascenta Capital and Janus Henderson Investors co-led). The investor base includes Atlas Venture, Cormorant, Goldman Sachs Alternatives, Fidelity, Deep Track Capital, OrbiMed, Viking Global Investors, Invus, Polaris Partners, Alexandria Venture Investments, Ascenta Capital and Janus Henderson. Headcount sits in the 11–50 range and the operating team is led by CEO Vishal Patel (formerly Flagship Pioneering, Novartis, Merck KGaA), CMO Bhaskar Srivastava (formerly Nimbus and Janssen, board-certified dermatologist), CSO and founding employee Jennifer Dovey (formerly Amgen, Biogen, Celgene), and COO Nicholas Scarchilli (formerly Biogen BD, Frankel Group, Raytheon). The company has received external recognition including the Fierce Biotech "Fierce 15" designation in 2025 and an EY Entrepreneur of the Year 2026 finalist nomination for the CEO.

Name

Triveni Bio

Legal name

Triveni Bio, Inc.

Website

https://triveni.bio

Company type

Private

Founded year

2023

Operating status

Operating

Headcount range

51–100 employees

Short description

Triveni Bio is a clinical-stage biotechnology company developing genetics-informed antibody therapeutics for immunological and inflammatory diseases, with a Phase 2 lead asset (TRIV-509, KLK5/7 inhibitor) for atopic dermatitis and a preclinical candidate (TRIV-920) for hereditary pancreatitis.

Ownership category

akta.pro rank

Product category

Antibody Therapeutics

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Monoclonal Antibody Therapeutics (mAbs) (HLAAAAAA)

Keywords

• Antibody therapeutics
• Inflammatory disease therapeutics
• Monoclonal antibody development
• Atopic dermatitis treatment
• Genetics-informed drug discovery

Headquarters

HQ city

Watertown

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Supply Chain, Infrastructure, Marketing or Sales

Revenue model

1. Pharmaceutical Development and Commercialization: Pre-revenue clinical-stage biotech company developing antibody therapeutics. Revenue will be generated through future pharmaceutical product sales upon regulatory approval.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Triveni Bio is a clinical-stage biotechnology company developing antibody-based therapeutics for immunological and inflammatory diseases. Its pipeline includes TRIV-509 (Phase 2, dual KLK5/7 inhibitor for atopic dermatitis), TRIV-573 (Phase 1, bispecific KLK5/7 plus IL-13 inhibitor for atopic dermatitis), and TRIV-920 (preclinical, dual trypsin 1/2 inhibitor for hereditary pancreatitis). Candidates are engineered using human genetics-driven target identification and proprietary antibody engineering to address root-cause disease biology.

Product overview

Triveni Bio is a clinical-stage biotechnology company developing a pipeline of differentiated antibody therapeutics for immunological and inflammatory disorders. The company's portfolio includes TRIV-509 (a first-in-class dual-specific monoclonal antibody targeting KLK5/7 for atopic dermatitis in Phase 2), TRIV-573 (a second-generation bispecific antibody combining KLK5/7 inhibition with anti-IL-13 for atopic dermatitis in Phase 1), and TRIV-920 (a first-in-class trypsin inhibitor for hereditary pancreatitis in preclinical development). All programs leverage the company's genetics-informed approach and advanced antibody engineering capabilities.

Differentiator

Problem solved

Functional benefit

Products and services

• TRIV-509 A first-in-class, dual-specific, half-life extended monoclonal antibody that inhibits active kallikreins 5 and 7 (KLK5/7) for the treatment of moderate-to-severe atopic dermatitis, designed to address inflammation, itch, and barrier disruption by targeting protease inhibition.
• TRIV-573 A second-generation, half-life extended bispecific antibody combining dual inhibition of KLK5/7 with a validated anti-IL-13 mechanism, targeting atopic dermatitis by addressing both barrier repair and Th2 inflammation with a single therapeutic.
• TRIV-920 A first-in-class monoclonal antibody with potent dual inhibition of active trypsin 1 and 2, in preclinical development for the treatment of hereditary pancreatitis; targets PRSS1R122H mutation with significant reduction in markers of acute and chronic pancreatic damage in preclinical models.

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• AbbVie (Rinvoq / Skyrizi): Markets Rinvoq (upadacitinib, JAK inhibitor) and Skyrizi (risankizumab, IL-23) across multiple inflammatory indications including atopic dermatitis. Represents established competition in the AD market with oral and biologic options.
• Sanofi/Regeneron (Dupixent): Developer and marketer of Dupixent (dupilumab), the dominant IL-4Rα-targeting biologic for atopic dermatitis and other type-2 inflammatory diseases. Triveni's KLK5/7 and IL-13 programs compete in the same AD market with a differentiated mechanism targeting barrier dysfunction.
• Incyte: Specialty biopharma with marketed dermatology product opzelura (ruxolitinib cream) for atopic dermatitis. Represents commercial-stage competition in the AD topical and broader I&I space.
• Galderma: Dermatology-focused specialty company marketing nemolizumab (IL-31) for atopic dermatitis and prurigo nodularis. Competes in the same specialty dermatology prescribing channel Triveni plans to target at launch.
• Eli Lilly (lebrikizumab / Ebglyss): Marketer of lebrikizumab, an IL-13-targeted antibody approved for atopic dermatitis. Triveni's TRIV-573 (which combines anti-IL-13 with KLK5/7 inhibition) directly overlaps with this mechanism, making Lilly a key clinical and commercial benchmark.

Emerging players

• Arcutis Biotherapeutics: Dermatology-focused clinical-stage biotech developing topical and systemic therapies for inflammatory skin diseases including atopic dermatitis. Comparable as a similarly positioned specialty dermatology R&D company targeting the same physician channel.
• Kymera Therapeutics: Clinical-stage biotech developing targeted protein degraders for immunology and oncology indications. Comparable as a similarly-sized clinical-stage biotech with innovative mechanism of action targeting inflammatory disease.
• Nimbus Therapeutics: Clinical-stage biotech developing structure-based drug design across metabolic and inflammatory disease. CMO Bhaskar Srivastava came from Nimbus, and the company represents a comparable small-cap immunology R&D model.

Regional players

• Almirall: European dermatology-focused specialty pharma with established AD portfolio (e.g., lebrikizumab EU rights). Comparable as a dermatology-specialized company targeting similar patient populations, though primarily serves European markets.

Direct peers

• AnaptysBio: Clinical-stage immunology biotech developing antibody therapeutics for I&I indications, including IL-36R antagonist (imsidolimab) and other inflammation targets. Closely comparable as a similarly-sized private/public antibody biotech with overlapping disease focus.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/triveni-bio

Revenue estimate

Valuation estimate

Number of profiles

Profiles15 records

Funding overview

Funding rounds3 records

Investors14 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Triveni Bio